

June 5, 2018
Fuji Pharma Co., Ltd.

**Announcement concerning commencement of preparations for Sales & Marketing Activities
for Fuji Pharma Branded Business in Thailand**

TOKYO, Japan June 5, 2018: Fuji Pharma Co., Ltd. (hereafter, 'Fuji Pharma') is pleased to announce that it has partnered with APO PLUS STATION (THAILAND) CO., LTD. as a service provider for the sales and marketing of Fuji Pharma's branded products in Thailand.

Fuji Pharma acquired OLIC (Thailand) Limited (hereafter, OLIC). OLIC became the largest pharmaceutical contract manufacturer in Thailand in October 2012. After the acquisition, Fuji Pharma invested substantially to upgrade the infrastructure and built a new state of the art parenteral facility. Fuji Pharma has completed the technology transfer for key parenteral products to the new facility at OLIC. In addition to Japan, the facility will also manufacture high quality injectable products for the Thailand market. Fuji Pharma group has already initiated regulatory filings for certain products in Thailand.

In the near future, Fuji Pharma will also launch its Japanese quality generic and novel products in obstetrics and gynecology therapy areas in Thailand. In ASEAN countries Fuji Pharma plans to establish a branded business through alliances with strategic business partners.

Overview of APO PLUS STATION (THAILAND) CO., LTD.

Representative: Mr. Suthas Thongprasert
Address: No. 308 Charasanitwong Soi 67, Bangplad, Bangkok, 10700 Thailand
Established: September 2016
Business: Business process outsourcing services for the non-core operations of clients
Main Shareholders: APO PLUS STATION CO., LTD. (99.7%)

Contact:

Fuji Pharma Co., Ltd.
Business Development Dept., Corporate Planning Div.
Tel: +81-3-3556-3344
Fax: +81-3-3556-4455